First US trial of bone-marrow stem cells for heart attack patients appears safe

The first randomized, placebo-controlled US clinical trial to assess the use of bone marrow-derived mononuclear cells in patients after a ST-elevation myocardial infarction (STEMI; severe heart attack) demonstrated a strong safety profile for this cell therapy, based on phase 1 results.

Read the whole article on Science Daily

More from Science Daily